# Haemonetics Corporation (HAE) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $102.92, market value $4.7 billion.

## Valuation
- **P/E (trailing): 49.7×** (5-yr avg 39.1×, 3-yr avg 27.6×). Haemonetics Corporation trades at 49.7× trailing earnings, well above its own five-year average of 39.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.9×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.5×**. Each dollar of revenue is priced at 3.5×.
- **Price / book: 5.6×**. The shares trade at 5.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 20.9×**. Enterprise value is 20.9× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 6.2%** (5-yr avg 4.4%). Free cash flow equals 6.2% of the market value, above its five-year average of 4.4%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 2.0%**. The inverse of the P/E: 2.0% of the price is earned each year.

## Profitability
- **Gross margin: 59.0%**. Haemonetics Corporation keeps 59.0% of revenue after the direct cost of what it sells.
- **Operating margin: 11.9%**. 11.9% of revenue is left after running the business.
- **Net margin: 7.3%**. 7.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.2%**. 12.2% on shareholders' equity is solid.
- **Return on invested capital: 7.1%**. Return on all capital, debt included, is 7.1%.
- **Return on assets: 4.0%**. Each dollar of assets produces 4.0% of profit.

## Growth
- **Revenue growth (1 yr): -2.0%** (3-yr 4.5%/yr, 5-yr 8.9%/yr). Revenue fell 2.0% over the last year, against 8.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -38.1%** (3-yr -2.9%/yr, 5-yr 5.8%/yr). Earnings per share fell 38.1%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 47.2%/yr**. Free cash flow has compounded at 47.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.54**. Debt is 1.54 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.6×**. It would take 3.6 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Haemonetics Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover Haemonetics Corporation; the consensus is buy, with an average price target of $106.40 (+3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 90.3%** (YTD 28.4%, 3-mo 44.4%). The shares are up 90.3% over twelve months including dividends.
- **From 52-week high: -6.1%** (117.5% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 65**. An RSI of 65 is neutral.
- **Beta (1 yr): 0.15** (volatility 49%). Beta of 0.15 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HAE · Page: https://foliofundamentals.com/stocks/hae

Not investment advice.